MyFinsight
Home
Blog
About
Proceeds from sale of
common stock and...
$4,347,972
(2.44%↑ Y/Y)
something is missing
$2,009,095
Net cash provided by
financing activities
$5,844,999
(19.33%↑ Y/Y)
Canceled cashflow
$512,068
Net increase in cash
$3,387,527
(456.44%↑ Y/Y)
Canceled cashflow
$2,457,472
Proceeds from exercise of
warrants
-$485,853
(-747.42%↓ Y/Y)
Payment of deferred
offering costs
$18,838
Proceeds from common
stock sold for cash...
-$7,377
(-101.28%↓ Y/Y)
Accounts payable,
accrued expenses and...
$419,025
(3808.19%↑ Y/Y)
Stock based
compensation
$125,114
(-68.73%↓ Y/Y)
Depreciation expense
$36,826
(-53.28%↓ Y/Y)
Due to related
parties
$26,750
(120.11%↑ Y/Y)
Net cash used in
operating activities
-$2,444,539
(42.91%↑ Y/Y)
Effect of foreign
exchange rate on changes...
-$12,933
(-72.53%↓ Y/Y)
Canceled cashflow
$607,715
Net loss
-$3,027,733
(35.64%↑ Y/Y)
Prepaid expenses and
other current assets
$24,521
(150.88%↑ Y/Y)
Back
Back
Cash Flow
Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc. (ENVB)
source: myfinsight.com